N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels

Documenti analoghi

• Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
  di: Gaudet, Daniel, et al.
  Pubblicazione: (2020)
• Treatment with Volanesorsen, a 2′-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3 mRNA, Does Not Affect the QTc Interval in Healthy Volunteers
  di: Watts, Lynnetta M., et al.
  Pubblicazione: (2020)
• Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis
  di: Boffa, Michael B., et al.
  Pubblicazione: (2019)
• The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
  di: Jan Borén, et al.
  Pubblicazione: (2020-07-01)
• The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
  di: Borén, Jan, et al.
  Pubblicazione: (2020)